Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.
Industry, Sector and Symbol
Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:AST
Previous SymbolNYSEMKT:AST
CUSIPN/A
Phone+1-510-4563805
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees31
Outstanding Shares55,660,000
Market Cap$0.00
OptionableOptionable
Asterias Biotherapeutics (NYSEAMERICAN:AST) Frequently Asked Questions
What is Asterias Biotherapeutics' stock symbol?
Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AST."
How were Asterias Biotherapeutics' earnings last quarter?
Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) posted its quarterly earnings results on Tuesday, March, 28th. The biotechnology company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.01. The biotechnology company had revenue of $1.75 million for the quarter, compared to analyst estimates of $2.81 million. View Asterias Biotherapeutics' Earnings History.
When is Asterias Biotherapeutics' next earnings date?
What price target have analysts set for AST?
3 equities research analysts have issued twelve-month price targets for Asterias Biotherapeutics' stock. Their forecasts range from $6.00 to $11.00. On average, they expect Asterias Biotherapeutics' share price to reach $8.50 in the next twelve months. This suggests a possible upside of 936.6% from the stock's current price. View Analyst Price Targets for Asterias Biotherapeutics.
What is the consensus analysts' recommendation for Asterias Biotherapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Asterias Biotherapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Asterias Biotherapeutics.
What are Wall Street analysts saying about Asterias Biotherapeutics stock?
Here are some recent quotes from research analysts about Asterias Biotherapeutics stock:
- 1. According to Zacks Investment Research, "Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company's technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. " (11/15/2018)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We use a sum-of- the-parts approach, which ascribes a $440M risk-adjusted net present value (rNPV) to the AST-OPC1 program in AST-VAC programs in NSCLC and prostate cancer." (9/5/2018)
Has Asterias Biotherapeutics been receiving favorable news coverage?
Press coverage about AST stock has been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Asterias Biotherapeutics earned a daily sentiment score of 1.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term.
Are investors shorting Asterias Biotherapeutics?
Asterias Biotherapeutics saw a decrease in short interest in the month of November. As of November 30th, there was short interest totalling 1,048,136 shares, a decrease of 64.1% from the November 15th total of 2,921,601 shares. Based on an average daily trading volume, of 291,180 shares, the days-to-cover ratio is currently 3.6 days. Currently, 3.2% of the shares of the company are short sold. View Asterias Biotherapeutics' Current Options Chain.
Who are some of Asterias Biotherapeutics' key competitors?
Some companies that are related to Asterias Biotherapeutics include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE), Ampliphi Biosciences (APHB) and Antibe Therapeutics (ATE).
Who are Asterias Biotherapeutics' key executives?
Asterias Biotherapeutics' management team includes the folowing people:
- Mr. Michael H. Mulroy, Chief Exec. Officer, Pres & Director (Age 52)
- Dr. Edward D. Wirth III, Chief Medical Officer (Age 53)
- Dr. Katharine E. Spink, Consultant (Age 44)
- Mr. Stephen L. Cartt, Advisor & Director (Age 55)
- Mr. Ryan D. Chavez, CFO & Gen. Counsel (Age 42)
Who are Asterias Biotherapeutics' major shareholders?
Asterias Biotherapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.34%). Company insiders that own Asterias Biotherapeutics stock include Edward Wirth, Katharine E Spink and Michael H Mulroy. View Institutional Ownership Trends for Asterias Biotherapeutics.
Which institutional investors are buying Asterias Biotherapeutics stock?
How do I buy shares of Asterias Biotherapeutics?
Shares of AST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Asterias Biotherapeutics' stock price today?
One share of AST stock can currently be purchased for approximately $0.82.
What is Asterias Biotherapeutics' official website?
How can I contact Asterias Biotherapeutics?
Asterias Biotherapeutics' mailing address is 6300 Dumbarton Cir, FREMONT, CA 94555-3644, United States. The biotechnology company can be reached via phone at +1-510-4563805.
MarketBeat Community Rating for Asterias Biotherapeutics (NYSEAMERICAN AST)
MarketBeat's community ratings are surveys of what our community members think about Asterias Biotherapeutics and other stocks. Vote "Outperform" if you believe AST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AST will underperform the S&P 500 over the long term. You may vote once every thirty days.
